| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Candidiasis | 14 | 2026 | 27 | 3.630 |
Why?
|
| Fungal Proteins | 15 | 2026 | 83 | 3.360 |
Why?
|
| Antifungal Agents | 10 | 2026 | 69 | 3.250 |
Why?
|
| Drug Resistance, Fungal | 10 | 2026 | 18 | 2.770 |
Why?
|
| Candida albicans | 15 | 2025 | 48 | 2.430 |
Why?
|
| HIV-1 | 11 | 2013 | 59 | 2.200 |
Why?
|
| HIV Infections | 12 | 2013 | 165 | 2.060 |
Why?
|
| Cell Wall | 5 | 2025 | 67 | 1.970 |
Why?
|
| Candida | 4 | 2025 | 23 | 1.850 |
Why?
|
| Benzopyrans | 5 | 2019 | 22 | 1.580 |
Why?
|
| Mitogen-Activated Protein Kinases | 3 | 2024 | 88 | 1.560 |
Why?
|
| Virulence | 15 | 2026 | 153 | 1.280 |
Why?
|
| Uterine Cervical Neoplasms | 4 | 2019 | 304 | 1.220 |
Why?
|
| Skin | 2 | 2025 | 153 | 1.020 |
Why?
|
| Tuberculosis | 2 | 2024 | 25 | 0.980 |
Why?
|
| Protein Kinases | 3 | 2015 | 155 | 0.980 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2024 | 33 | 0.960 |
Why?
|
| Host-Pathogen Interactions | 2 | 2025 | 92 | 0.930 |
Why?
|
| Lysine Acetyltransferases | 1 | 2025 | 1 | 0.920 |
Why?
|
| MicroRNAs | 5 | 2022 | 302 | 0.820 |
Why?
|
| Nanoparticles | 5 | 2023 | 291 | 0.810 |
Why?
|
| Prostatic Neoplasms | 3 | 2022 | 302 | 0.790 |
Why?
|
| Aptamers, Nucleotide | 1 | 2022 | 13 | 0.780 |
Why?
|
| Amphotericin B | 1 | 2022 | 19 | 0.750 |
Why?
|
| Humans | 47 | 2026 | 28870 | 0.730 |
Why?
|
| Signal Transduction | 8 | 2019 | 1469 | 0.720 |
Why?
|
| Mice | 22 | 2026 | 4808 | 0.720 |
Why?
|
| Animals | 28 | 2026 | 10699 | 0.720 |
Why?
|
| Mitochondria | 3 | 2015 | 408 | 0.710 |
Why?
|
| Viral Load | 5 | 2013 | 32 | 0.660 |
Why?
|
| Antineoplastic Agents | 5 | 2019 | 686 | 0.650 |
Why?
|
| Drug Repositioning | 1 | 2019 | 12 | 0.620 |
Why?
|
| Fungi | 2 | 2021 | 58 | 0.610 |
Why?
|
| Bacterial Proteins | 4 | 2024 | 497 | 0.600 |
Why?
|
| Pancreatic Neoplasms | 7 | 2026 | 548 | 0.560 |
Why?
|
| Cell Proliferation | 11 | 2026 | 825 | 0.550 |
Why?
|
| Cell Line, Tumor | 15 | 2026 | 1351 | 0.540 |
Why?
|
| Azoles | 4 | 2026 | 7 | 0.530 |
Why?
|
| Microbial Sensitivity Tests | 7 | 2026 | 149 | 0.530 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2012 | 98 | 0.520 |
Why?
|
| Apoptosis | 9 | 2026 | 780 | 0.520 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2013 | 60 | 0.510 |
Why?
|
| India | 11 | 2026 | 147 | 0.510 |
Why?
|
| Th17 Cells | 2 | 2013 | 33 | 0.500 |
Why?
|
| Adaptation, Physiological | 4 | 2021 | 173 | 0.490 |
Why?
|
| Curcumin | 5 | 2016 | 69 | 0.480 |
Why?
|
| Xenograft Model Antitumor Assays | 11 | 2026 | 275 | 0.470 |
Why?
|
| Female | 22 | 2024 | 15631 | 0.460 |
Why?
|
| CD4-Positive T-Lymphocytes | 4 | 2012 | 112 | 0.460 |
Why?
|
| Mice, Nude | 7 | 2026 | 332 | 0.450 |
Why?
|
| Carcinogenesis | 3 | 2019 | 81 | 0.440 |
Why?
|
| Biofilms | 3 | 2024 | 122 | 0.440 |
Why?
|
| Phosphoproteins | 1 | 2015 | 120 | 0.440 |
Why?
|
| Th1 Cells | 1 | 2013 | 36 | 0.410 |
Why?
|
| Immunophenotyping | 3 | 2012 | 61 | 0.410 |
Why?
|
| Gene Expression Regulation, Fungal | 5 | 2019 | 26 | 0.410 |
Why?
|
| Neoplasms | 1 | 2023 | 874 | 0.410 |
Why?
|
| Interleukin-17 | 2 | 2013 | 52 | 0.410 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 47 | 0.400 |
Why?
|
| Antiretroviral Therapy, Highly Active | 3 | 2011 | 9 | 0.400 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2013 | 3 | 0.400 |
Why?
|
| Heat-Shock Proteins | 1 | 2013 | 38 | 0.390 |
Why?
|
| Gene Expression Regulation | 2 | 2019 | 634 | 0.390 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2026 | 104 | 0.380 |
Why?
|
| CD4 Antigens | 1 | 2012 | 18 | 0.380 |
Why?
|
| Gene Deletion | 7 | 2024 | 120 | 0.370 |
Why?
|
| Serum Albumin | 2 | 2011 | 35 | 0.370 |
Why?
|
| Membrane Potential, Mitochondrial | 4 | 2019 | 30 | 0.350 |
Why?
|
| Drug Monitoring | 1 | 2011 | 36 | 0.350 |
Why?
|
| Alternative Splicing | 2 | 2021 | 48 | 0.340 |
Why?
|
| Hemoglobins | 1 | 2011 | 118 | 0.330 |
Why?
|
| Mutation | 4 | 2026 | 867 | 0.300 |
Why?
|
| Magnetite Nanoparticles | 3 | 2015 | 17 | 0.300 |
Why?
|
| Male | 18 | 2022 | 13931 | 0.300 |
Why?
|
| gag Gene Products, Human Immunodeficiency Virus | 4 | 2013 | 7 | 0.290 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2022 | 138 | 0.290 |
Why?
|
| Histidine Kinase | 3 | 2015 | 10 | 0.270 |
Why?
|
| Histone Acetyltransferases | 2 | 2019 | 15 | 0.270 |
Why?
|
| Lymphocyte Activation | 1 | 2008 | 210 | 0.270 |
Why?
|
| Erythrocytes | 3 | 2019 | 89 | 0.260 |
Why?
|
| DNA | 2 | 2022 | 377 | 0.260 |
Why?
|
| Transcription Factors | 4 | 2022 | 523 | 0.250 |
Why?
|
| Guinea Pigs | 2 | 2024 | 73 | 0.250 |
Why?
|
| Candida tropicalis | 1 | 2026 | 2 | 0.250 |
Why?
|
| Immune Evasion | 1 | 2026 | 9 | 0.240 |
Why?
|
| Rad52 DNA Repair and Recombination Protein | 1 | 2005 | 1 | 0.240 |
Why?
|
| Immunologic Tests | 1 | 2005 | 3 | 0.240 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2005 | 11 | 0.240 |
Why?
|
| Ribosomes | 1 | 2026 | 32 | 0.240 |
Why?
|
| Chromosomes, Fungal | 1 | 2005 | 10 | 0.240 |
Why?
|
| Adult | 12 | 2013 | 8026 | 0.230 |
Why?
|
| Blood Proteins | 3 | 2015 | 68 | 0.220 |
Why?
|
| Middle Aged | 9 | 2013 | 7415 | 0.220 |
Why?
|
| Oxidative Stress | 6 | 2024 | 677 | 0.220 |
Why?
|
| Genes, Regulator | 1 | 2003 | 11 | 0.210 |
Why?
|
| Transcriptome | 2 | 2022 | 231 | 0.210 |
Why?
|
| Klebsiella pneumoniae | 2 | 2014 | 29 | 0.210 |
Why?
|
| Endocytosis | 3 | 2019 | 96 | 0.200 |
Why?
|
| Indocyanine Green | 1 | 2023 | 16 | 0.200 |
Why?
|
| Tyrphostins | 1 | 2022 | 4 | 0.200 |
Why?
|
| Scattering, Small Angle | 1 | 2022 | 5 | 0.200 |
Why?
|
| Erythrokeratodermia Variabilis | 1 | 2022 | 3 | 0.200 |
Why?
|
| X-Ray Diffraction | 1 | 2022 | 41 | 0.190 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2019 | 8 | 0.190 |
Why?
|
| Candidiasis, Invasive | 1 | 2022 | 1 | 0.190 |
Why?
|
| Echinocandins | 1 | 2022 | 3 | 0.190 |
Why?
|
| Bifidobacterium pseudocatenulatum | 1 | 2022 | 1 | 0.190 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2022 | 28 | 0.190 |
Why?
|
| Membrane Transport Proteins | 4 | 2017 | 79 | 0.180 |
Why?
|
| Introns | 1 | 2021 | 43 | 0.180 |
Why?
|
| Histone Chaperones | 1 | 2021 | 4 | 0.180 |
Why?
|
| Hemolysis | 2 | 2019 | 51 | 0.170 |
Why?
|
| Stress, Physiological | 2 | 2020 | 96 | 0.170 |
Why?
|
| Materials Testing | 2 | 2019 | 89 | 0.170 |
Why?
|
| Cell Line | 1 | 2023 | 700 | 0.170 |
Why?
|
| Polyglycolic Acid | 3 | 2016 | 38 | 0.170 |
Why?
|
| Nitrogen | 1 | 2021 | 78 | 0.170 |
Why?
|
| Drug Resistance, Multiple, Fungal | 1 | 2020 | 1 | 0.170 |
Why?
|
| Chromatin | 1 | 2021 | 76 | 0.170 |
Why?
|
| Bacteria | 2 | 2022 | 286 | 0.170 |
Why?
|
| Lipids | 1 | 2022 | 218 | 0.170 |
Why?
|
| Colorectal Neoplasms | 1 | 2022 | 142 | 0.160 |
Why?
|
| Lactic Acid | 3 | 2016 | 94 | 0.160 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 2 | 2010 | 3 | 0.160 |
Why?
|
| Triterpenes | 1 | 2019 | 9 | 0.160 |
Why?
|
| Disease Models, Animal | 4 | 2019 | 1508 | 0.160 |
Why?
|
| Molecular Biology | 1 | 2019 | 17 | 0.160 |
Why?
|
| Clone Cells | 1 | 2019 | 22 | 0.160 |
Why?
|
| ATP-Binding Cassette Transporters | 2 | 2017 | 38 | 0.160 |
Why?
|
| beta Catenin | 2 | 2017 | 66 | 0.160 |
Why?
|
| Serum | 1 | 2019 | 11 | 0.160 |
Why?
|
| Benzimidazoles | 1 | 2019 | 32 | 0.160 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 6 | 0.160 |
Why?
|
| Imidazoles | 1 | 2019 | 63 | 0.150 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2019 | 54 | 0.150 |
Why?
|
| Genome, Bacterial | 1 | 2019 | 72 | 0.150 |
Why?
|
| Protein Binding | 4 | 2015 | 667 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 2 | 2014 | 536 | 0.150 |
Why?
|
| Droughts | 1 | 2019 | 23 | 0.150 |
Why?
|
| Deoxycytidine | 2 | 2019 | 67 | 0.150 |
Why?
|
| Tubulin | 1 | 2019 | 32 | 0.150 |
Why?
|
| Mucins | 2 | 2019 | 25 | 0.150 |
Why?
|
| Tubulin Modulators | 1 | 2019 | 17 | 0.150 |
Why?
|
| Indoles | 1 | 2019 | 111 | 0.150 |
Why?
|
| Oryza | 1 | 2019 | 42 | 0.150 |
Why?
|
| Gene Expression Regulation, Plant | 1 | 2019 | 74 | 0.140 |
Why?
|
| Young Adult | 5 | 2013 | 2835 | 0.140 |
Why?
|
| Plant Proteins | 1 | 2019 | 67 | 0.140 |
Why?
|
| DNA, Bacterial | 1 | 2019 | 309 | 0.140 |
Why?
|
| Papillomavirus Infections | 1 | 2019 | 149 | 0.140 |
Why?
|
| Cell Survival | 1 | 2019 | 419 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2019 | 268 | 0.140 |
Why?
|
| Phylogeny | 2 | 2026 | 493 | 0.130 |
Why?
|
| Microbiota | 1 | 2018 | 98 | 0.130 |
Why?
|
| Vacuoles | 1 | 2016 | 11 | 0.120 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2015 | 20 | 0.120 |
Why?
|
| Protein Transport | 2 | 2013 | 158 | 0.110 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 1658 | 0.110 |
Why?
|
| CD57 Antigens | 2 | 2011 | 3 | 0.110 |
Why?
|
| Chemical Phenomena | 1 | 2015 | 22 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 472 | 0.110 |
Why?
|
| Virulence Factors | 1 | 2015 | 45 | 0.110 |
Why?
|
| Genes, MDR | 1 | 2014 | 6 | 0.110 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2014 | 29 | 0.110 |
Why?
|
| HIV Long-Term Survivors | 1 | 2013 | 2 | 0.110 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2013 | 133 | 0.100 |
Why?
|
| Biomimetic Materials | 1 | 2013 | 20 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 35 | 0.100 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2013 | 44 | 0.100 |
Why?
|
| Caenorhabditis elegans | 1 | 2013 | 61 | 0.100 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2014 | 146 | 0.100 |
Why?
|
| ADP-ribosyl Cyclase 1 | 1 | 2012 | 10 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2019 | 170 | 0.090 |
Why?
|
| HLA-DR Antigens | 1 | 2012 | 29 | 0.090 |
Why?
|
| Biological Evolution | 1 | 2013 | 101 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 300 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2012 | 39 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 119 | 0.090 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2013 | 233 | 0.090 |
Why?
|
| Interleukin-7 Receptor alpha Subunit | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cell Differentiation | 2 | 2011 | 427 | 0.090 |
Why?
|
| RNA, Viral | 2 | 2011 | 68 | 0.090 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 2011 | 4 | 0.090 |
Why?
|
| Adolescent | 3 | 2010 | 3194 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2013 | 697 | 0.090 |
Why?
|
| CD28 Antigens | 1 | 2011 | 11 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2013 | 344 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2012 | 149 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2013 | 1056 | 0.090 |
Why?
|
| Biomarkers | 2 | 2011 | 777 | 0.090 |
Why?
|
| Nanostructures | 1 | 2011 | 64 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 296 | 0.080 |
Why?
|
| Viremia | 1 | 2010 | 16 | 0.080 |
Why?
|
| Phosphorylation | 2 | 2019 | 585 | 0.080 |
Why?
|
| Cytokines | 1 | 2012 | 451 | 0.080 |
Why?
|
| Heat-Shock Response | 2 | 2013 | 13 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2010 | 100 | 0.080 |
Why?
|
| RNA, Ribosomal, 16S | 2 | 2022 | 327 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 2 | 2009 | 278 | 0.070 |
Why?
|
| Dendritic Cells | 1 | 2010 | 143 | 0.070 |
Why?
|
| Prognosis | 1 | 2011 | 811 | 0.070 |
Why?
|
| Blotting, Western | 2 | 2014 | 515 | 0.070 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 29 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 118 | 0.070 |
Why?
|
| Cross-Sectional Studies | 2 | 2010 | 995 | 0.070 |
Why?
|
| DNA-Binding Proteins | 2 | 2019 | 490 | 0.070 |
Why?
|
| Drug Carriers | 3 | 2015 | 119 | 0.070 |
Why?
|
| Prospective Studies | 1 | 2011 | 1280 | 0.070 |
Why?
|
| CD4 Lymphocyte Count | 3 | 2012 | 13 | 0.070 |
Why?
|
| Macrophages | 2 | 2021 | 305 | 0.070 |
Why?
|
| Neoplasm Metastasis | 2 | 2019 | 164 | 0.070 |
Why?
|
| Cell Cycle | 2 | 2019 | 163 | 0.070 |
Why?
|
| Drug Delivery Systems | 3 | 2015 | 236 | 0.060 |
Why?
|
| Biological Transport | 2 | 2017 | 128 | 0.060 |
Why?
|
| Infant | 2 | 2010 | 1025 | 0.060 |
Why?
|
| Breast Neoplasms | 1 | 2012 | 483 | 0.060 |
Why?
|
| Hydrogen Peroxide | 2 | 2004 | 145 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2010 | 1173 | 0.060 |
Why?
|
| Multilocus Sequence Typing | 1 | 2026 | 3 | 0.060 |
Why?
|
| Genome, Fungal | 1 | 2026 | 8 | 0.060 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2019 | 328 | 0.060 |
Why?
|
| Whole Genome Sequencing | 1 | 2026 | 25 | 0.060 |
Why?
|
| Organelle Biogenesis | 1 | 2026 | 13 | 0.060 |
Why?
|
| DNA Ligase ATP | 1 | 2005 | 1 | 0.060 |
Why?
|
| DNA Ligases | 1 | 2005 | 1 | 0.060 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2005 | 3 | 0.060 |
Why?
|
| Antibodies, Protozoan | 1 | 2005 | 9 | 0.060 |
Why?
|
| Antigens, Protozoan | 1 | 2005 | 9 | 0.060 |
Why?
|
| Ubiquitination | 1 | 2026 | 33 | 0.060 |
Why?
|
| Gene Dosage | 1 | 2005 | 35 | 0.060 |
Why?
|
| Leishmania | 1 | 2005 | 6 | 0.060 |
Why?
|
| Karyotyping | 1 | 2005 | 25 | 0.060 |
Why?
|
| Heterozygote | 1 | 2005 | 69 | 0.060 |
Why?
|
| Protozoan Proteins | 1 | 2005 | 54 | 0.060 |
Why?
|
| Genomics | 1 | 2026 | 125 | 0.060 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2004 | 9 | 0.060 |
Why?
|
| Tuberculosis Vaccines | 1 | 2024 | 6 | 0.050 |
Why?
|
| Genotype | 1 | 2005 | 461 | 0.050 |
Why?
|
| Genes, Reporter | 1 | 2004 | 87 | 0.050 |
Why?
|
| Vitamin K 3 | 1 | 2003 | 1 | 0.050 |
Why?
|
| Kidney | 1 | 2005 | 289 | 0.050 |
Why?
|
| tert-Butylhydroperoxide | 1 | 2003 | 7 | 0.050 |
Why?
|
| Superoxides | 1 | 2003 | 62 | 0.050 |
Why?
|
| Child | 2 | 2010 | 2291 | 0.050 |
Why?
|
| Cell Division | 1 | 2003 | 154 | 0.050 |
Why?
|
| Sodium Chloride | 1 | 2003 | 67 | 0.050 |
Why?
|
| Particle Size | 2 | 2015 | 105 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 202 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2003 | 194 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2004 | 115 | 0.050 |
Why?
|
| Up-Regulation | 1 | 2003 | 247 | 0.050 |
Why?
|
| Semen | 1 | 2022 | 29 | 0.050 |
Why?
|
| Corynebacterium | 1 | 2022 | 9 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2016 | 292 | 0.050 |
Why?
|
| Bacteroides | 1 | 2022 | 15 | 0.050 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2022 | 68 | 0.050 |
Why?
|
| Bacteroidetes | 1 | 2022 | 16 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2003 | 612 | 0.050 |
Why?
|
| RNA Precursors | 1 | 2021 | 9 | 0.050 |
Why?
|
| Spliceosomes | 1 | 2021 | 11 | 0.050 |
Why?
|
| Lung | 1 | 2024 | 382 | 0.040 |
Why?
|
| Bacterial Toxins | 1 | 2024 | 273 | 0.040 |
Why?
|
| Proteolysis | 1 | 2021 | 59 | 0.040 |
Why?
|
| Genetic Loci | 1 | 2021 | 77 | 0.040 |
Why?
|
| Statistics, Nonparametric | 2 | 2011 | 82 | 0.040 |
Why?
|
| Eye Proteins | 1 | 2022 | 207 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 477 | 0.040 |
Why?
|
| Mining | 1 | 2019 | 3 | 0.040 |
Why?
|
| Glucosyltransferases | 1 | 2019 | 3 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 404 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 36 | 0.040 |
Why?
|
| Environmental Microbiology | 1 | 2019 | 25 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2019 | 209 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 97 | 0.040 |
Why?
|
| Metagenomics | 1 | 2019 | 57 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 212 | 0.040 |
Why?
|
| Ethylenes | 1 | 2019 | 5 | 0.040 |
Why?
|
| Blotting, Northern | 1 | 2019 | 46 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 841 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2019 | 139 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2022 | 485 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2022 | 415 | 0.040 |
Why?
|
| Phagocytosis | 1 | 2019 | 80 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2019 | 95 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2019 | 453 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 377 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2020 | 668 | 0.030 |
Why?
|
| Fluorescence Recovery After Photobleaching | 1 | 2017 | 5 | 0.030 |
Why?
|
| Cell Movement | 1 | 2019 | 376 | 0.030 |
Why?
|
| Paclitaxel | 1 | 2019 | 200 | 0.030 |
Why?
|
| Fluconazole | 1 | 2017 | 12 | 0.030 |
Why?
|
| Molecular Docking Simulation | 1 | 2017 | 53 | 0.030 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2017 | 82 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 120 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2009 | 1022 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 787 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2015 | 29 | 0.030 |
Why?
|
| Aged | 1 | 2005 | 5598 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2015 | 124 | 0.030 |
Why?
|
| Adsorption | 1 | 2015 | 33 | 0.030 |
Why?
|
| Static Electricity | 1 | 2015 | 35 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2015 | 106 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2015 | 270 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 156 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2014 | 34 | 0.030 |
Why?
|
| Heterografts | 1 | 2014 | 66 | 0.030 |
Why?
|
| Genes, Fungal | 1 | 2014 | 10 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2014 | 114 | 0.030 |
Why?
|
| Quorum Sensing | 1 | 2014 | 6 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2014 | 26 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 196 | 0.030 |
Why?
|
| Membrane Lipids | 1 | 2014 | 22 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2014 | 113 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 133 | 0.030 |
Why?
|
| Prostate-Specific Antigen | 1 | 2014 | 54 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 190 | 0.030 |
Why?
|
| Biocompatible Materials | 1 | 2015 | 95 | 0.030 |
Why?
|
| Membrane Microdomains | 1 | 2014 | 39 | 0.030 |
Why?
|
| Transfection | 1 | 2014 | 319 | 0.030 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2013 | 5 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 465 | 0.030 |
Why?
|
| Biological Availability | 1 | 2013 | 44 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2013 | 28 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2013 | 137 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2013 | 130 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2013 | 110 | 0.020 |
Why?
|
| Tumor Microenvironment | 1 | 2014 | 194 | 0.020 |
Why?
|
| CD4-CD8 Ratio | 1 | 2011 | 2 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2012 | 82 | 0.020 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2011 | 54 | 0.020 |
Why?
|
| Polyethyleneimine | 1 | 2011 | 18 | 0.020 |
Why?
|
| Nanomedicine | 1 | 2012 | 62 | 0.020 |
Why?
|
| Anti-HIV Agents | 1 | 2011 | 20 | 0.020 |
Why?
|
| Interleukins | 1 | 2012 | 112 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2011 | 101 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 391 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2010 | 8 | 0.020 |
Why?
|
| Receptors, CCR5 | 1 | 2010 | 4 | 0.020 |
Why?
|
| CD40 Antigens | 1 | 2010 | 14 | 0.020 |
Why?
|
| Delayed Diagnosis | 1 | 2010 | 19 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 86 | 0.020 |
Why?
|
| Anti-Retroviral Agents | 1 | 2010 | 16 | 0.020 |
Why?
|
| Receptors, CXCR4 | 1 | 2010 | 29 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 292 | 0.020 |
Why?
|
| Immunodominant Epitopes | 1 | 2008 | 13 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 467 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2008 | 46 | 0.020 |
Why?
|
| Neutrophils | 1 | 2009 | 185 | 0.020 |
Why?
|
| Time Factors | 1 | 2012 | 1613 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2008 | 108 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2008 | 257 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 737 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2008 | 202 | 0.020 |
Why?
|
| Risk Factors | 1 | 2010 | 2126 | 0.010 |
Why?
|
| Culture Media | 1 | 2004 | 99 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2010 | 2635 | 0.010 |
Why?
|
| Phenotype | 1 | 2004 | 686 | 0.010 |
Why?
|